Kailera Therapeutics, Inc. KLRA
—
11.22
(0.76)
(6.34%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow KLRA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
11.11 | 9.67 | 12.01 | — |
+2 more quarters Free account |
Net Debt/EBITDA |
7.56 | 6.14 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.70 | 0.87 | 0.00 | 0.91 | |
Capex/Depreciation |
0.00 | 0.00 | (6.74) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.76) | (3,162.50) | 0.00 | 0.00 | |
Cash per Share |
8.97 | 24,035.83 | 0.00 | 0.00 | |
Shareholders Equity per Share |
10.94 | 25,938.70 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
10.94 | 25,938.70 | 0.00 | 0.00 | |
Free Cash Flow |
(77.53) | (68.31) | (122.30) | (26.23) | |
Working Capital |
845.52 | 475.48 | 511.13 | — | |
Capital Expenditures |
— | — | (2.09) | — | |
Net Current Asset Value |
836.22 | 465.84 | 501.15 | 0.00 | |
| Other line items | |||||
Quick Ratio |
10.96 | 9.47 | 11.77 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.76) | (3,162.50) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Assets |
605.71 | 401.60 | — | — | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | — | 0.00% |
Columns are period end dates